Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to ...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many pharmaceutical companies have promised to build.

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

A spokesperson confirmed the company plans to reduce its workforce by “less than 20%,” months after significantly lowering ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

Since becoming Vertex's top scientist in 2015, Altshuler has shaped the company’s efforts to expand beyond cystic fibrosis.

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step ...